查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197819

眼科手術輔助器具市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Ophthalmic Viscosurgical Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，眼科手術輔助市場預計將以 6.5% 的複合年增長率增長。

最初，隨著全球 COVID-19 病例的增加，世界各國政府實施了封鎖措施以阻止 SARS-CoV-2 病毒的傳播，開設了眼科診所和醫院。不僅醫院就診人數下降，但是許多程序被取消或推遲，不僅影響了患者，也影響了研究市場。 例如，根據 Parul C Gupta 及其同事於 2021 年在印度眼科學雜誌上發表的一項研究，接受調查的診所預計將進行 7,500 例白內障手術。 然而，由於大流行，只能提供 2,500 台手術。 數據表明，在 COVID-19 大流行期間，白內障手術顯著減少。 Gabriel Ayubet.al 發表的一項研究表明，總數分別減少了 92.52%、93.84%、72.74% 和 19.63%。 數據顯示，COVID-19對眼科疾病的診斷和治療產生了負面影響，對市場產生了負面影響。 此外，自解除限制和供應鏈正常化以來，市場已經強勁復甦。 門診人數的增加和對眼科手術的所有限制的取消正在推動預測期內的市場復甦。

這是由於人口迅速老齡化、糖尿病患病率增加以及白內障和青光眼手術數量增加所致。 隨著世界老齡化人口的增加，人們更容易患上眼疾。 例如，根據世界衛生組織（WHO）2021年10月發布的數據，人口老齡化的速度比過去快得多，到2030年，全球六分之一的人將超過10歲。據報導，60歲以上 預計 60 歲及以上人口的比例將從 2020 年的 10 億增加到 2030 年的 14 億。 因此，預計人口老齡化加劇將在預測期內推動市場增長。

糖尿病會損害您的眼睛並導致視力下降或失明。 糖尿病患者可能會遇到各種稱為糖尿病眼病的眼部問題。 這些疾病包括青光眼、白內障、糖尿病性黃斑、糖尿病性視網膜病變等。因此，糖尿病患病率的增加預計將導致眼部疾病，從而促進市場增長。 例如，根據 IDF 糖尿病地圖集第十版 2021，糖尿病將在 2021 年影響全球約 5.37 億人（20-79 歲）。 預計到 2030 年糖尿病將影響 6.43 億人，到 2045 年將影響 7.83 億人。 因此，糖尿病是眼病最常見的原因，糖尿病患病率的增加預計將在預測期內提振市場。

但是，替代療法的可用性可能會阻礙市場增長。

眼科手術輔助設備的市場趨勢

白內障手術領域有望健康成長

預計將推動白內障手術領域發展的關鍵因素是白內障患病率上升和全球老年人口不斷增加。 例如，根據 2021 年 1 月發表在 Sage Journal 上的一項研究，2020 年東非每百萬居民中有 3,000 至 10,000 例新病例。 埃塞俄比亞有超過 500,000 例失明病例和 120 萬例嚴重視力損傷病例，白內障是可預防性失明和視力損傷的主要原因。 白內障是所有年齡段視力喪失的第二大原因，佔全球失明病例的 50% 和低視力病例的 33%，導致全球白內障和白內障相關疾病的增加。可以看出， 因此，對白內障手術設備的需求不斷增加，推動了該行業的增長。

此外，白內障手術的增加預計將在預測期內推動內臟手術設備市場的需求。 根據經濟合作與發展組織 (OECD) 的數據，到 2022 年，愛爾蘭的白內障手術人數將增加到 25,942 人，以色列的白內障手術人數到 2020 年將增加到 71,920 人。 此外，2020 年韓國的白內障手術數量增加到 702,621 例。 因此，預計白內障手術的增加將推動對粘彈性手術器械市場的需求，從而促進細分市場的增長。

此外，主要市場參與者推出的產品將在整個預測期內進一步擴大市場。 例如，博士倫在 2021 年 4 月報告稱，美國食品和藥物管理局 (FDA) 批准了 ClearVisc 分散眼科手術輔助劑 (OVD) 用於眼科手術。

因此，上述所有因素都有望在預測期內推動市場增長。

預計在預測期內北美將佔據很大的市場份額

由於人口老齡化、眼科醫療設施的普及、醫療支出的增加以及醫療基礎設施的完善，預計北美將佔據全球眼科手術救助市場的很大份額。. 根據美國疾病控制和預防中心 2021 年的數據，到 2020 年，美國將有大約 3010 萬人患有白內障。 此外，美國疾病控制與預防中心 2020 年發布的數據顯示，到 2050 年，由於美國糖尿病和其他慢性病患病率上升，約有 896 萬美國人將出現無法矯正的視力喪失。 因此，預計眼病患病率的增加將在預測期內推動市場增長。

此外，眼科疾病高發的老齡化人口有望推動市場擴張。 根據加拿大統計局的數據，到 2022 年 4 月，700 萬加拿大人（佔人口的 19.0%）將在 2021 年達到或超過 65 歲。 與 0-14 歲的兒童相比，65 歲及以上的人口每六年翻一番。 因此，預計老年人口的增加將在預測期內推動市場增長。

此外，市場參與者採用的各種有機和無機策略可能會支持市場的增長。 例如，2022 年 8 月，Glaukos Corporation 就 iStent infinite 獲得了美國食品和藥物管理局 (FDA) 的 510(k) 許可。 這是一種海綿體微旁路術，用作降低原發性開角型青光眼患者升高的眼內壓 (IOP) 的唯一手術，該患者先前的藥物和手術治療無法控制。

因此，上述所有因素都有望在預測期內推動市場增長。

眼科手術輔助用品市場競爭者分析

眼科手術輔助設備市場競爭適中，由幾家大型企業組成。 目前主導市場的公司包括強生公司、Carl Zeiss Meditec AG、Bausch & Lomb Incorporated、Rayner Intraocular Lenses Limited、Alcon AG、Beaver-Visitec International Inc、Bohus Biotech AB、Truviz Ophthalmic、Amring Pharmaceutical Inc.。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 老年人口迅速增加
    • 糖尿病患病率增加
    • 白內障和青光眼手術的數量增加
  • 市場製約因素
    • 替代療法的可用性
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按類型
    • 凝聚力
    • 去中心化
    • 黏合劑
  • 按供應來源
    • 生物
    • 動物起源
    • 半合成
  • 通過使用
    • 青光眼手術
    • 白內障手術
    • 角膜移植
    • 其他用途
  • 區域信息
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Johnson & Johnson
    • Carl Zeiss Meditec AG
    • Bausch & Lomb Incorporated
    • Rayner Intraocular Lenses Limited
    • Alcon AG
    • Beaver-Visitec International Inc.
    • Bohus Biotech AB
    • Truviz Ophthalmic
    • Amring Pharmaceutical Inc.
    • Advin Health Care
    • Ophtechnics Unlimited
    • EC21 Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 69159

The ophthalmic viscosurgical devices market is expected to register a CAGR of 6.5% during the forecast period.

Initially, with the increasing COVID-19 cases around the world, governments around the globe implemented lockdown measures to stop the spread of the SARS-CoV-2 virus, which not only led to a drop in footfall in clinics and hospitals for eye care but also led to the cancellation or postponement of many procedures which had its impact on the patients as well as the studied market. For instance, according to a research study published by Parul C Gupta et al. in 2021 in the Indian Journal of Ophthalmology, the studied clinic was expected to perform 7,500 cataract procedures. Still, due to the pandemic, they could serve only 2,500 procedures. This data suggested a significant decrease in cataract procedures during the COVID-19 pandemic. As per the research study published by Gabriel Ayubet. al., in November 2021, on the comparison of the pre-pandemic and pandemic periods data for glaucoma patients in a tertiary center, it was observed the total number of outpatient clinical visits, visual field exams, surgical procedures, and medications released decreased by 92.52%, 93.84%, 72.74%, and 19.63%, respectively. This data shows a negative impact of COVID-19 on diagnosing and treating ocular disorders; thus, the market suffered negatively. Moreover, the market has been making a strong comeback since the limitations were lifted and normalized the supply chain. Increased outpatient visits and the removal of all restrictions on ophthalmic procedures have been driving the market recovery over the projected period.

This is attributed to the rapidly increasing geriatric population, increasing prevalence of diabetes, and an increasing number of cataract and glaucoma surgeries performed. The rising geriatric population worldwide is more prone to ocular disorders. For instance, the data published in October 2021 by the World Health Organization (WHO) reported that the pace of population aging is much faster than in the past, and by 2030, 1 in 6 people in the world will be aged 60 years or over. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion by 2030. Thus, an increase in the geriatric population is expected to boost market growth over the forecast period.

Diabetes can damage the eyes, resulting in vision problems or even blindness. People with diabetes may experience various eye issues known as diabetic eye disease. These ailments include glaucoma, cataracts, diabetic macular, and diabetic retinopathy, and thus growing prevalence of diabetes is expected to cause eye diseases, thereby boosting the market growth. For instance, according to the IDF Diabetes Atlas Tenth Edition 2021, diabetes has affected around 537 million persons (20-79 years) in 2021 across the world. Diabetes is expected to affect 643 million people by 2030 and 783 million by 2045. Thus, the increasing prevalence of diabetes, the most common cause of ophthalmic disease, is expected to boost the market over the forecast period.

However, the availability of alternative procedures may hamper the market growth.

Ophthalmic Viscosurgical Devices Market Trends

Cataract Surgery Segment is Estimated to Witness Healthy Growth

The significant factors expected to drive growth in the cataract surgery segment are the increasing prevalence of cataracts and the growing geriatric population globally. For instance, according to the research study published in Sage Journal in January 2021, there were between 3,000 and 10,000 new cases per million inhabitants in East Africa in 2020. With more than 0. 5 million cases of blindness and 1. 2 million cases of severe visual impairment, cataract was the primary reason for preventable blindness and impaired vision in Ethiopia. A cataract is the second-leading cause of impaired vision in persons of all ages, accounting for 50% of all cases of blindness and 33% of all cases of low vision globally, which shows an increase in cataract and cataract-related illnesses globally. Thus, the demand for cataract surgery devices for treatment is increasing, fueling growth in the segments.

Moreover, a growing number of cataract surgeries is expected to drive the demand for the viscosurgical devices market over the forecast period. According to the Organization for Economic Co-operation and Development (OECD), in 2022, cataract surgeries in Ireland climbed to 25,942 in 2020, and cataract procedures in Israel increased to 71,920 in 2020. Furthermore, the number of cataract procedures conducted in Korea increased to 702,621 in 2020. Thus, rising cataract surgeries are expected to drive the demand in the viscosurgical devices market, thereby boosting segment growth.

Furthermore, product launch by the key market players further expands the market throughout the forecast period. For instance, in April 2021, Bausch + Lomb reported that the United States Food and Drug Administration (FDA) approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery.

Thus, all the above factors are expected to boost market growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market during the Forecast Period

North America is expected to hold a significant market share in the global ophthalmic viscosurgical devices market due to the increasing aging population, improved access to ophthalmic care facilities, increasing healthcare expenditure, and well-established healthcare infrastructure. According to the Centers for Disease Control and Prevention 2021, about 30.1 million people were affected by cataracts in the United States in 2020. Additionally, per data published by the Centers for Disease Control and Prevention in 2020, around 8.96 million Americans will suffer from uncorrectable vision impairment by 2050 due to the increasing epidemics of diabetes and other chronic diseases in the United States. Thus, increasing the prevalence of ophthalmic diseases is expected to boost market growth over the forecast period.

Additionally, a senior population that is more prone the ophthalmic diseases is expected to support the market expansion. According to Statistics Canada, in April 2022, 7 million people, or 19.0% of the population, in Canada were 65 years or older in 2021. The number of seniors 65 and over doubles every six years compared to children ages 0 to 14. Thus, rising in the geriatric population is expected to boost the market growth over the forecast period.

Moreover, various organic and inorganic strategies adopted by the market players are likely to support the market's growth. For instance, in August 2022, Glaukos Corporation received 510(k) clearance from the United States Food and Drug Administration (FDA) for the iStent infinite. It is a trabecular micro-bypass system indicated for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.

Thus, all the above factors are expected to boost market growth over the forecast period.

Ophthalmic Viscosurgical Devices Market Competitor Analysis

The ophthalmic viscosurgical devices market is moderately competitive and consists of several major players. Some of the companies currently dominating the market include Johnson & Johnson, Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, Rayner Intraocular Lenses Limited, Alcon AG, Beaver-Visitec International Inc., Bohus Biotech AB, Truviz Ophthalmic, and Amring Pharmaceutical Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapidly Increasing Geriatric Population
    • 4.2.2 Increasing Prevalence of Diabetes
    • 4.2.3 Increasing Number of Cataract and Glaucoma Surgeries Performed
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatment Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Type
    • 5.1.1 Cohesive
    • 5.1.2 Dispersive
    • 5.1.3 Viscoadaptive
  • 5.2 By Source
    • 5.2.1 Biological
    • 5.2.2 Animal
    • 5.2.3 Semi-synthetic
  • 5.3 By Application
    • 5.3.1 Glaucoma Surgery
    • 5.3.2 Cataract Surgery
    • 5.3.3 Corneal Grafting
    • 5.3.4 Other Applications
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Johnson & Johnson
    • 6.1.2 Carl Zeiss Meditec AG
    • 6.1.3 Bausch & Lomb Incorporated
    • 6.1.4 Rayner Intraocular Lenses Limited
    • 6.1.5 Alcon AG
    • 6.1.6 Beaver-Visitec International Inc.
    • 6.1.7 Bohus Biotech AB
    • 6.1.8 Truviz Ophthalmic
    • 6.1.9 Amring Pharmaceutical Inc.
    • 6.1.10 Advin Health Care
    • 6.1.11 Ophtechnics Unlimited
    • 6.1.12 EC21 Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS